Rigel Pharmaceuticals, Incorporated

Bergenbio Asa

Bergen Teknologioverføring As

Bergen Teknologioverforing As

Bergenbio As

Bergebio Asa

James Bradley Lorens

David Robert Micklem

Sacha Holland

Sergej Kiprijanov

Linn Nilsson

Lavina Ahmed

Tone Sandal

Todd M Kinsella

Mark K Bennett

Todd R Pray

Weiduan Xu

Jakob Maria Bogenberger

Robert E Atchison

Annabelle Friera

Gro Gausdal

Lars Akslen

The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.

Anti-axl antagonistic antibodies

Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.

Anti-Axl antagonistic antibodies

An Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.

Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus

The present disclosure relates to antibodies that specifically bind a novel epitope on the AxI protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.

The invention relates to the control of gene expression. Specifically, the invention provides compositions and methods for the production and use of recombinant nucleic acid molecules that have the ability to specifically downregulate an expressed target gene in vivo. In some aspects, the invention provides methods for producing a hairpin DNA molecule where part of the molecule is derived from an mRNA that is a target for a small interfering RNA (siRNA) derived from the hairpin. In other aspects, the invention provides synthetic hairpin adapter oligonucleotides that are used in the construction of siRNA-producing cassettes. In other aspects, the invention provides methods for testing for the presence or absence of specific inhibitory activity of an RNAi trigger molecule, and in still other aspects, the invention provides methods for identifying an active RNAi trigger molecule from a library of RNAi trigger molecules. In still other aspects, the invention provides methods for identifying a polynucleotide from a plurality of candidate target polynucleotides that is specifically targeted by an RNAi trigger molecule. In other aspects, the invention provides epi-allelic series of hypomorphic RNAi trigger molecules specific for any gene of interest, where the series of RNAi trigger molecules have a variety of uses including analysis of gene function and drug target development.

Methods for creating and identifying functional RNA interference elements

The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.

In vivo production of cyclic peptides for inhibiting protein-protein interaction

The present invention relates to regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of endothelial cell haptotaxis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.

Modulators of angiogenesis and tumorigenesis

The present invention relates to regulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.

Modulators of angiogenesis

The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding 'angiogenesis regulatory proteins and nucleic acids' which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.

Growing community of inventors

Bønes, Norway

James Bradley Lorens